구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA |
Overview Company | Thomas Martin, MD |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | Multiple Myeloma; Recurrent Multiple Myeloma |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | AAV) but is clinically still in an early developmental stage |
MoA Mechanism | CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI |
MoA Biomarker | biomarkers such as body composition metrics |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Clinical Pharmacology of Lisocabtagene Maraleucel in B-cell Malignancies.. Chimeric antigen receptor (CAR) T-cell therapies represent a distinct therapeutic modality whose clinical activity is governed by in vivo cellular kinetics. Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed, 4-1BB CAR T-cell product in which in vivo expansion plays an important role in clinical pharmacology… |
Toxicology CRS | Reported |
Clinical Safety signal | Clinical Pharmacology of Lisocabtagene Maraleucel in B-cell Malignancies.. Chimeric antigen receptor (CAR) T-cell therapies represent a distinct therapeutic modality whose clinical activity is governed by in vivo cellular kinetics. Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed, 4-1BB CAR T-cell product in which in vivo expansion plays an important role in clinical pharmacology… |
Clinical Selected reported efficacy | ORR 97.1% |
Clinical Reported ORR | 97.1% |
Clinical Reported PFS | NA |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03548207 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03548207 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA |
Overview Company | Thomas Martin, MD |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | Multiple Myeloma; Recurrent Multiple Myeloma |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | AAV) but is clinically still in an early developmental stage |
MoA Mechanism | CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI |
MoA Biomarker | biomarkers such as body composition metrics |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Clinical Pharmacology of Lisocabtagene Maraleucel in B-cell Malignancies.. Chimeric antigen receptor (CAR) T-cell therapies represent a distinct therapeutic modality whose clinical activity is governed by in vivo cellular kinetics. Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed, 4-1BB CAR T-cell product in which in vivo expansion plays an important role in clinical pharmacology… |
Toxicology CRS | Reported |
Clinical Safety signal | Clinical Pharmacology of Lisocabtagene Maraleucel in B-cell Malignancies.. Chimeric antigen receptor (CAR) T-cell therapies represent a distinct therapeutic modality whose clinical activity is governed by in vivo cellular kinetics. Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed, 4-1BB CAR T-cell product in which in vivo expansion plays an important role in clinical pharmacology… |
Clinical Selected reported efficacy | ORR 97.1% |
Clinical Reported ORR | 97.1% |
Clinical Reported PFS | NA |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03548207 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03548207 |
추천 비교
추천 비교